Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBT Margin (2019 - 2025)

Historic EBT Margin for Neurogene (NGNE) over the last 5 years, with Q1 2025 value amounting to 28491.25%.

  • Neurogene's EBT Margin rose 256572000.0% to 28491.25% in Q1 2025 from the same period last year, while for Sep 2025 it was 108471.25%, marking a year-over-year increase of 1301489600.0%. This contributed to the annual value of 8184.43% for FY2024, which is N/A changed from last year.
  • Neurogene's EBT Margin amounted to 28491.25% in Q1 2025, which was up 256572000.0% from 2014.27% recorded in Q2 2024.
  • In the past 5 years, Neurogene's EBT Margin registered a high of 408700.0% during Q1 2023, and its lowest value of 2014.27% during Q2 2024.
  • Moreover, its 3-year median value for EBT Margin was 15662.65% (2024), whereas its average is 109502.76%.
  • Per our database at Business Quant, Neurogene's EBT Margin crashed by 2000000000bps in 2024 and then surged by 256572000bps in 2025.
  • Over the past 3 years, Neurogene's EBT Margin (Quarter) stood at 408700.0% in 2023, then tumbled by -100bps to 2014.27% in 2024, then soared by 1514bps to 28491.25% in 2025.
  • Its EBT Margin was 28491.25% in Q1 2025, compared to 2014.27% in Q2 2024 and 2834.05% in Q1 2024.